DLBCL

View All

antibody-drug-conjugate-pipeline
Insights into the Evolving Landscape of Antibody-Drug Conjugate (ADC) & the Key Companies in the Segment

In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market - Adectr...

Find More

latest pharma news
MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic’s IMU-838 promising results

MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...

Find More